DGAP-News

STRATEC signed an agreement to acquire the BioSciences business of Sony DADC - Seite 2

is expected after closing. The company currently has approximately 120
employees. The company valuation set in the sale and purchase agreement
amounts over EUR 30 million.

Comments Marcus Wolfinger, CEO of STRATEC: "With the acquisition of Sony
DADC BioSciences, we are expanding the STRATEC Group to include an
innovation leader in a very attractive growth market. This combination of
an experienced, highly qualified team with innovative products and
established customer relationships is an ideal addition to STRATEC's
product portfolio. After closing this acquisition we will be able to offer
solutions to our customers from a significantly broader technology
spectrum, one that encompasses entirely new solutions in the field of smart
consumables. We have been co-operating with the team in Anif in several
major development projects for several years now and are impressed by their
professionalism and innovative power. We believe that pooling our strengths
this way will help us to access new growth opportunities for the STRATEC
Group while also diversifying cluster risks."

Dr. Chris Mauracher, Managing Director of Sony DADC BioSciences added: "The
two business models are very similar in terms of their partnership-driven
approach, transferring development activities into continuous cash flow
generating production. Given our different positions within the same value
chain, we thus complement each other ideally. This combination now enables
us to offer complete solutions comprising instrumentation, consumables and
smart consumables from one single source. From a customer perspective, that
reduces the number of contact partners and thus the complexity and process
risk. We are optimistic that this will soon also be reflected in an even
better offer to order ratio with our partners."

About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, as system solutions to
laboratories, blood banks and research institutes around the world. The
company develops its products on the basis of its own patented
technologies.
Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.

About Sony DADC BioSciences GmbH
Building on Sony DADC's experience in high-precision optical disc
manufacturing, Sony DADC BioSciences partners with Life Sciences and